Companies › Guangzhou Excelmab
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EX103 CD3 and CD20 bispecific monoclonal antibody | CD3E, CD20 | Phase 1 | CD20-positive Non-Hodgkin Lymphoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06021678 | EX103 | Phase 1 | CD20-positive Non-Hodgkin Lymphoma | Oncology | Oct 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.